iTeos Therapeutics (NASDAQ:ITOS) Announces Quarterly Earnings Results

iTeos Therapeutics (NASDAQ:ITOS) issued its quarterly earnings results on Wednesday. The company reported ($1.01) EPS for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.13, Zacks reports.

iTeos Therapeutics Trading Down 2.0 %

ITOS opened at $6.85 on Wednesday. The company has a market cap of $250.26 million, a P/E ratio of -2.17 and a beta of 1.38. The business’s 50-day moving average price is $7.54 and its 200-day moving average price is $9.57. iTeos Therapeutics has a 12 month low of $6.67 and a 12 month high of $18.75.

Analysts Set New Price Targets

A number of research firms recently commented on ITOS. Wells Fargo & Company reduced their target price on iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating on the stock in a research note on Thursday, December 19th. Wedbush restated an “outperform” rating and set a $25.00 price target on shares of iTeos Therapeutics in a research report on Friday, January 10th. Finally, HC Wainwright restated a “buy” rating and set a $21.00 price target on shares of iTeos Therapeutics in a research report on Thursday, January 16th.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.